Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 4/20 | 0.64 |
| ▸ | CSF1R | P07333 | 4/20 | 0.64 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | KIT | P10721 | 5/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436860 | 1.00 | BTK (0.65) | BTKLCKCSF1RABL1KIT | |
| Toluene SCHEMBL28768811 | 0.94 | ALDH1A1 (0.66) | BTKLCKCSF1RABL1KIT | |
| SCHEMBL27795076 | 0.90 | TNF (0.63) | BTKLCKCSF1RABL1HDAC6 | |
| SCHEMBL15381992 | 0.90 | BTK (0.69) | BTKLCKCSF1RABL1KIT | |
| SCHEMBL31721288 | 0.88 | HPGDS (0.59) | BTKLCKCSF1RABL1KIT | |
| SCHEMBL4006161 | 0.87 | BTK (0.63) | BTKLCKCSF1RABL1KIT | |
| SCHEMBL27846346 | 0.87 | BTK (0.63) | BTKLCKCSF1RABL1KIT | |
| SCHEMBL846574 | 0.86 | BTK (0.65) | BTKLCKCSF1RABL1KIT | |
| SCHEMBL30080653 | 0.86 | KIT (0.66) | BTKLCKCSF1RABL1KIT | |
| SCHEMBL17936182 | 0.86 | KIT (0.66) | BTKLCKCSF1RABL1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658290-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-15 | — | — | EP | claimed |
| CN-100451015-C | Preparing method of imatinib | HANGZHOU SHENGMEI MEDICINE TEC (CN) | 2009-01-14 | — | — | CN | claimed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | claimed |
| CN-101016293-A | Preparing method of imatinib | HANGZHOU SHENGMEI MEDICINE TEC (CN) | 2007-08-15 | — | — | CN | claimed |
| JP-2007504159-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | claimed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | claimed |
| WO-2023135330-A1 | DEOXYCYTIDINE KINASE INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-07-20 | — | — | WO | disclosed |
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-9573928-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2017-02-21 | — | — | US | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20060142580-A1 | an N-phenyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide claimed intermediate easily prepared by amidation of the aniline and the benzoic acid; reaction with a 2-aminopyrimidine to produce antitumor tyrosine kinase inhibitor | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| CN-1630648-A | N-phenyl-2-pyrimidinamine derivatives | NOVARTIS AG (CH) | 2005-06-22 | — | — | CN | disclosed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
| EP-1474408-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003066613-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142580-A1 | an N-phenyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide claimed intermediate easily prepared by amidation of the aniline and the benzoic acid; reaction with a 2-aminopyrimidine to produce antitumor tyrosine kinase inhibitor | ERBB2, ABL1, ABL2 | BTK 83/4885LCK 185/4885CSF1R 2192/4885 |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | BTK 18/4885LCK 28/4885CSF1R 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.